iPads Are the Tablet of Choice Among U.S. Physicians

MONTREAL--(BUSINESS WIRE)--As the tech world awaits today’s unveiling of the iPad 2, one group of professional users has already demonstrated intense loyalty for Apple’s first tablet. According to an online survey of 341 U.S. healthcare professionals (HCPs) completed in February 2011, 79% would choose Apple’s iPad for professional use. Their overwhelming preference for the iPad is in sharp contrast with Windows PC and Android-based tablets at 12 percent and 9 percent, respectively.

“The research indicates that the Apple iPad is going to be an ever more important part of a HCP's daily life as a tool to enhance productivity and remaining up to date with the latest developments in their medical field”

Aptilon Corporation, (TSX-V: APZ), a leader in online access to and interaction with HCPs on behalf of pharmaceutical sales and marketing programs, used its ReachNet^SMPhysician Access Channel to recruit HCP participation in a survey on tablet and mobile technology. Between February 7 and February 16, 2011, 341 HCPs from throughout the U.S. participated in the survey.

Among the responding HCPs that already have an iPad, 59 percent said they use the device for medically related tasks, including receiving and reviewing information updates, as a tool during their standard practice, and to complete paperwork. Rapidly becoming an essential platform for HCPs, the survey revealed that about 38 percent of U.S. HCPs will own an Apple iPad within the next year. In another sign of high demand for the device among medical practitioners, additional respondents said they would use an iPad if supplied to them by a third party or an employer.

“The research indicates that the Apple iPad is going to be an ever more important part of a HCP's daily life as a tool to enhance productivity and remaining up to date with the latest developments in their medical field,” said Aptilon COO Mark Benthin. “As the number of HCPs using iPads increases, Aptilon expects to see increasing opportunities for interactions between industry professionals and HCPs seeking relevant medical content using their tablets.”

Live interaction between HCPs and pharmaceutical representatives is available on the iPad through Aptilon’s mobile connectivity platform. Through both iPads and smartphones, HCPs can engage in relevant live and self-directed activities at their convenience. During the live interaction, the HCP discussion with a representative is enhanced through content shared and displayed to the HCP on an iPad in real-time.

For more information on the survey methodology, questions and responses, call or email the media or investor contacts listed below.

About Aptilon Corporation

Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach, advertise to and and interact with more than 500,000 US physicians via the Internet through its innovative AxcelRx^SM service offering, which includes video detailing, mobile detailing, ReachNet^SMPhysician Access Channel, the DMD database and permission-based email services. Top US pharmaceutical companies and respected healthcare organizations have adopted Aptilon's solutions to market to and engage leading physicians. For more information, visit www.aptilon.com.

AxcelRx^SMand ReachNet^SM are service marks of Aptilon Corporation.

Forward-Looking Statements

This news release may contain forward-looking statements. These statements relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management of Aptilon. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Aptilon does not assume any obligation to update or revise them to reflect new events or circumstances.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.